Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Axitinib (Primary) ; Everolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms EVAX
- 05 Sep 2017 Results published in the European Journal of Cancer.
- 22 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 Planned End Date changed from 1 Feb 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.